Log in
Enquire now
‌

US Patent 10570119 Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)

Patent 10570119 was granted and assigned to Merrimack Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
Current Assignee
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10570119
Patent Inventor Names
Dmitri B. Kirpotin0
Suresh K. Tipparaju0
Alexander Koshkaryev0
Bolin Geng0
Daryl C. Drummond0
Ozan Alkan0
Date of Patent
February 25, 2020
Patent Application Number
16069092
Date Filed
January 11, 2017
Patent Citations Received
‌
US Patent 11787781 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
‌
US Patent 11028076 Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)
0
Patent Primary Examiner
‌
Brian J Davis
Patent abstract

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10570119 Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us